RB loss promotes prostate cancer metastasis

Chellappagounder Thangavel, Ettickan Boopathi, Yi Liu, Alex Haber, Adam Ertel, Anshul Bhardwaj, Sankar Addya, Noelle Williams, Stephen J. Ciment, Paolo Cotzia, Jeffry L. Dean, Adam Snook, Chris McNair, Matt Price, James R. Hernandez, Shuang G. Zhao, Ruth Birbe, James B. McCarthy, Eva A. Turley, Kenneth J. PientaFelix Y. Feng, Adam P. Dicker, Karen E. Knudsen, Robert B. Den

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


RB loss occurs commonly in neoplasia but its contributions to advanced cancer have not been assessed directly. Here we show that RB loss in multiple murine models of cancer produces a prometastatic phenotype. Gene expression analyses showed that regulation of the cell motility receptor RHAMM by the RB/E2F pathway was critical for epithelial- mesenchymal transition, motility, and invasion by cancer cells. Genetic modulation or pharmacologic inhibition of RHAMM activity was sufficient and necessary for metastatic phenotypes induced by RB loss in prostate cancer. Mechanistic studies in this setting established that RHAMM stabilized F-actin polymerization by controlling ROCK signaling. Collectively, our findings show how RB loss drives metastatic capacity and highlight RHAMM as a candidate therapeutic target for treating advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)982-995
Number of pages14
JournalCancer Research
Issue number4
StatePublished - Feb 15 2017

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'RB loss promotes prostate cancer metastasis'. Together they form a unique fingerprint.

Cite this